Latest from Cleveland Clinic

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.
Robert Dean, MD, staff physician, Cleveland Clinic, discusses challenges in the mantle cell lymphoma (MCL) paradigm.
Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses resistance to BTK inhibition in chronic lymphocytic leukemia (CLL).
Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.
An approach using machine learning to analyze genomic and clinical data from patients with myelodysplastic syndromes could replace the gold standard of predicting how long patients may live with the disease. 
Robert Dean, MD, a staff physician at Cleveland Clinic, discusses ongoing research on biomarkers in mantle cell lymphoma (MCL).
Robert Dean, MD, discusses the promise for new therapies in mantle cell lymphoma.
Brian T. Hill, MD, PhD, assistant professor, Hematology and Oncology, Cleveland Clinic, discusses the progression of treatment of patients with chronic lymphocytic leukemia.
 
Publication Bottom Border
Border Publication
x